【摘要】 基于"起始"基因JAK2、CALR和MPL突变的检测,以及骨髓病理形态学分析的标准化和用MPN-10对患者疾病相关症状负荷进行评估,使更为精准地诊断骨髓增殖性肿瘤(MPN)成为可能。其诊断模式也已从"临床-病理诊断"模式过渡到"临床-病理-分子诊断"模式。JAK2抑制剂的上市,使改变MPN患者自然病程成为可能。文章介绍了进一步规范中国现阶段MPN临床诊治中的几个关键问题。更多还原

【Abstract】 Based on the detection of "driver" JAK2, CALR and MPL gene mutations, the standardization of bone marrow morphologic analysis, and the assessment of symptom burden using MPN-10, it is possible to achieve the most accurate diagnosis of MPN. The diagnostic model of MPN has been moved from clinical-pathology to clinical-pathological-molecular. Nowadays, JAK2 inhibitors treatment may change the natural history of MPN. Some key points for diagnosis and treatment of MPN in China were discussed in this paper.更多还原